Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
GLP-1 Clinical Trials for Alzheimers The ELAD Study: First Proof of Concept The first major human study tested liraglutide in 204 people with mild Alzheimers disease over one year
Employers indicated the following coverage for GLP-1 drugs: 56% provide coverage for diabetes only (down from 66% in 2024) 31% provide coverage for both diabetes and weight loss (up from 17% in 2024)
And more disruption is yet to come: as new drugs enter the market
Medication access : Previously, there were shortages of semaglutide and tirzepatide injections
Virology Journal
Judge Karen Spencer Marston presides over MDL 3094 in the Eastern District of Pennsylvania after the Judicial Panel on Multidistrict Litigation established this consolidation in February 2024
